A promising treatment, retatrutide, is creating considerable anticipation within the Aussie weight management community. Developed by Lilly , this dual GIP and GLP-1 agonist appears to deliver more impressive outcomes than present therapies. Initial scientific research have shown remarkable decreases in overall fat , indicating the potential for a